Article

Production of interleukin-10 in asthmatic children after Beta-1-3-glucan

Maternal and Child Department of Universidade Federal de Pernambuco, Brazil.
Allergologia et Immunopathologia (Impact Factor: 1.58). 07/2009; 37(4):188-92. DOI: 10.1016/j.aller.2009.02.005
Source: PubMed

ABSTRACT Beta-1-3 Glucan is a polysaccharide extracted from Saccharomyces cerevisiae with a possible immunomodulating action that may have a favourable action on asthma symptoms and other allergic diseases. An experimental study carried out using a murine respiratory model detected a decrease in pulmonary tissue eosinophilia, as well as an increase in Interleukin-10 (IL-10) after glucan use.
This open, exploratory study with blind outcome evaluation included asthmatic children between 6 and 12 years of age with mild to moderate persistent asthma and inadequate disease control (rescue medication needed more than twice a week) in spite of inhaled budesonide 400 microg/day. After a four week run-in period, subcutaneous Beta-1-3-glucan injections were given weekly for the first four weeks and then every two weeks for the last four weeks. IL-10 levels, measured by the immunoenzymatic method (ELISA), were compared before and after glucan administration.
Twenty patients (14 male and 6 female) were included. Mean IL-10 levels were 6.4 pg/ml and 11.3 pg/ml before and after glucan, respectively (p = 0.02). There was also a reduction of asthmatic symptoms score at the end of study.
This is the first study which shows that subcutaneous particulate Beta-1-3-glucan increases serum IL-10 levels in asthmatics. The possibility of glucan being able to modulate allergic sensitisation and having a beneficial action in restoring Th2 function should be assessed by means of properly planned controlled clinical trials, as it may represent a new therapeutic strategy.

1 Follower
 · 
136 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This randomized, placebo-controlled, double-blind study compared the effects of daily supplementation for 4 week with 250 mg Wellmune WGP® β-1,3/1,6-Glucan (WGP) with placebo 250 mg/day (rice flour) on physical and psychological health attributes of self-described "moderate" ragweed allergy sufferers. Study participants (mean age = 36 ± 9 year; range 18-53 year) were recruited before the beginning of ragweed season (September) in Northeastern Ohio. Serum IgE concentration, allergy symptoms [via self-report, Visual Analog Scale (VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)], psychological well-being [Profile of Mood States (POMS)], and physical function (RAND SF-36 Medical Outcomes Study) were measured immediately prior to and after supplementation with WGP (n = 24) or placebo (n = 24) for 4 weeks. Data were analyzed using repeated measures analyses of variance (ANOVA). Compared with placebo, WGP reduced total allergy symptoms (28%), symptom severity (52%), and symptom rating on the VAS (37%) (P < 0.05), but had no effect on serum IgE levels. As measured by the POMS, WGP increased participants' rating of vigor (10%), but reduced tension (34%), depression (45%), anger (41%), fatigue (38%), and confusion (34%) (P < 0.05). Study participants given WGP reported increased physical health (11%), energy (19%), and emotional well-being (7%) compared with study participants given the placebo (RAND SF-36 Medical Outcomes Study). The WGP group also reported decreased sleep problems (53%), reduced nasal symptoms (59%), eye symptoms (57%), non-nasal symptoms (50%), activities (53%), emotions (57%), and improved quality of life (QOL) (56%), as well as improved global mood state (13%). Supplementation with WGP for 4 weeks improved allergy symptoms, overall physical health, and emotional well-being compared with placebo in self-described "moderate" ragweed allergy sufferers during ragweed allergy season.
    Food Science & Nutrition 01/2013; 1(1):90-101. DOI:10.1002/fsn3.11
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Mould exposure has been linked to childhood asthma and bronchial hyper-responsiveness. Few studies have assessed beta-(1,3)-d-glucan (beta-glucan), a significant fungal cell wall constituent, in relation to asthma in adolescence. Objective To determine whether house dust-derived beta-glucan exposure at age 7–10 is associated with the development and persistence of atopic and non-atopic asthma, and bronchial hyper-responsiveness (BHR) by age 11–14. Methods Dust samples were collected from the 1995 Study of Asthma, Genes, and Environment (SAGE) birth cohort. This cohort was derived from Manitoba provincial healthcare administrative records of children high and low risk for asthma. Samples were collected from the homes of 422 children at age 7–10 and analyzed using beta-glucan and endotoxin-specific Limulus Amoebocyte Lysate assays. Asthma, atopy, and BHR status of each child were also assessed at ages 7–10 and 11–14. Results At age 7–10, beta-glucan dust levels in the home were associated with persistent atopic asthma at age 11–14 (OR 1.79 for each unit increase in levels, 95% CI 1.14–2.81), independent of endotoxin exposure, and Alternaria or Cladosporium sensitization. The likelihood of BHR almost doubled with unit increases in dust beta-glucan in asthmatic children. In children without asthma, exposure to high beta-glucan levels at age 7–10 also elevated risk for BHR in adolescence (OR 1.74, 95% CI 1.05–2.89). New-onset atopic asthma was twice more likely following high beta-glucan exposure in children without asthma but the association did not reach statistical significance. No associations were evident with concurrent asthma phenotype at age 7–10 or non-atopic asthma at age 11–14. Conclusion These findings implicate home beta-glucan exposure at school-age as a risk factor for persistent atopic asthma and new-onset BHR. The higher prevalence of BHR in urban adolescents may be propagated by this home exposure.
    PLoS ONE 06/2014; 9(6):e98878. DOI:10.1371/journal.pone.0098878 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 1,3‑β‑glucan is considered a fungal biomarker and exposure to this agent induces lung inflammation. Previous studies have shown that 1,3‑β‑glucan affects Th1 and Th2 immune responses. Interleukin (IL)‑10 and transforming growth factor (TGF)‑β, as typical anti‑inflammatory cytokines, suppress the Th1 immune response. To investigate the effects of 1,3‑β‑glucan on the secretion of cytokines in co‑cultured mouse macrophages and lymphocytes in vitro, mice were exposed to 1,3‑β‑glucan or phosphate‑buffered saline (PBS) by intratracheal instillation. Following extraction and co‑culture of macrophages and lymphocytes, which were treated with or without 1,3‑β‑glucan in vitro, enzyme‑linked immunosorbent assay (ELISA) was used to detect the levels of cytokines and real‑time reverse transcription (RT)‑polymerase chain reaction (PCR) was used to investigate the mRNA expression of forkhead box p3 (Foxp3) in the cells. We showed that 1,3‑β‑glucan exposure in vitro decreased the secretion of Th1 cytokines and increased the secretion of Th2 cytokines in the culture media. Furthermore, 1,3‑β‑glucan exposure in vitro increased the secretion of IL‑10 and TGF‑β in the culture media. According to these results, 1,3‑β‑glucan exposure in vitro is suggested to promote the secretion of anti‑inflammatory cytokines, which may lead to a decrease in the levels of Th1 cytokines and an increase in the levels of Th2 cytokines. 1,3‑β‑Glucan is suggested to induce regulatory lymphocytes, which partly contributes to an increased secretion of anti‑inflammatory cytokines in co‑cultured mouse macrophages and lymphocytes in vitro.
    Molecular Medicine Reports 06/2013; 8(2). DOI:10.3892/mmr.2013.1553 · 1.48 Impact Factor

Full-text

Download
3 Downloads
Available from
Mar 18, 2015